Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone403-670-7377
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable
Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."
How were Oncolytics Biotech's earnings last quarter?
Oncolytics Biotech, Inc. (NASDAQ:ONCY) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.07. View Oncolytics Biotech's Earnings History.
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONCY?
1 brokers have issued 12-month target prices for Oncolytics Biotech's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Oncolytics Biotech's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 175.2% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.
What is the consensus analysts' recommendation for Oncolytics Biotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.
Has Oncolytics Biotech been receiving favorable news coverage?
News headlines about ONCY stock have trended extremely negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oncolytics Biotech earned a news impact score of -4.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Oncolytics Biotech.
Are investors shorting Oncolytics Biotech?
Oncolytics Biotech saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,740,000 shares, an increase of 14.5% from the December 15th total of 1,520,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is currently 1.2 days. Approximately 6.7% of the shares of the stock are short sold. View Oncolytics Biotech's Current Options Chain.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Rigel Pharmaceuticals (RIGL), Mirum Pharmaceuticals (MIRM), Aptorum Group (APM), Assembly Biosciences (ASMB), Mallinckrodt (MNK), Verrica Pharmaceuticals (VRCA), Arcus Biosciences (RCUS), Beyondspring (BYSI), Catalyst Pharmaceuticals (CPRX), Innate Pharma (IPHYF), BioSpecifics Technologies (BSTC), Urovant Sciences (UROV), ProQR Therapeutics (PRQR), Progenics Pharmaceuticals (PGNX) and DURECT (DRRX).
What other stocks do shareholders of Oncolytics Biotech own?
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look, Chief Financial Officer
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Dr. Rita Laeufle, Chief Medical Officer
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
How do I buy shares of Oncolytics Biotech?
Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONCY stock can currently be purchased for approximately $3.27.
How big of a company is Oncolytics Biotech?
What is Oncolytics Biotech's official website?
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]
MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
